Drug Trial Radar · NCT02286947
Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy
Last checked: Nov 20, 2026Latest source record: Mar 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Nov 2014
Primary completion
Apr 21, 2017
Study completion Mar 23, 2018
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 7 years, up to 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to explore safety and tolerability of eteplirsen in participants with advanced stage Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
Conditions
- Muscular Dystrophy, Duchenne
Interventions
EteplirsenDrug
Eteplirsen solution for IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment Emergent Adverse EventsTime frame: From first dose of drug up to 100 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Ronald Reagan UCLA Medical Center
Los Angeles, California
University of California, Davis Medical Center
Sacramento, California
University of Iowa Children's Hospital
Iowa City, Iowa
Kennedy Krieger Institute
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
St. Louis Children's Hospital
St Louis, Missouri
University of Rochester Medical Center
Rochester, New York
Nationwide Children's Hospital
Columbus, Ohio
Seattle Children's Hospital
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.